1. Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial 
Issaka Sagara, PhD, Abdoul Habib Beavogui, PhD, Issaka Zongo, PhD, Issiaka Soulama, PhD, Isabelle Borghini-Fuhrer, PhD, Bakary Fofana, MD, Daouda Camara, MSc, Anyirékun F Somé, PhD, Aboubacar S Coulibaly, MD, Oumar B Traore, MD, Niawanlou Dara, PharmD, Moïse J T Kabore, MD, Ismaila Thera, MSc, Yves D Compaore, MD, Malick Minkael Sylla, MD, Frederic Nikiema, MD, Mamadou Saliou Diallo, MD, Alassane Dicko, PhD, Jose Pedro Gil, PhD, Steffen Borrmann, MD, Stephan Duparc, MD, Robert M Miller, FRCS, Ogobara K Doumbo, PhD, Jangsik Shin, MSc, Anders Bjorkman, PhD, Jean-Bosco Ouedraogo, PhD, Sodiomon B Sirima, PhD, Prof Abdoulaye A Djimdé, PhD 
The Lancet Infectious Diseases 
Volume 16, Issue 2, Pages (February 2016)
DOI: /S (15)
Copyright © 2016 Sagara et al. Open Access article distributed under the terms of CC BY-NC-ND Terms and Conditions

2. Figure 1
Trial profile
The Lancet Infectious Diseases  , DOI: ( /S (15) )
Copyright © 2016 Sagara et al. Open Access article distributed under the terms of CC BY-NC-ND Terms and Conditions

3. Figure 2
Peak bilirubin versus peak alanine aminotransferase or aspartate aminotransferase on or after day 3 following first treatment (episode 1) or re-treatment (episode 2+) with pyronaridine-artesunate or artemether-lumefantrine
ULN=upper limit of normal.
The Lancet Infectious Diseases  , DOI: ( /S (15) )
Copyright © 2016 Sagara et al. Open Access article distributed under the terms of CC BY-NC-ND Terms and Conditions

4. Figure 3
Incidence of adverse events after pyronaridine-artesunate for first malaria episode and re-treatment of subsequent malaria episodes by time from first treatment to re-treatment
The Lancet Infectious Diseases  , DOI: ( /S (15) )
Copyright © 2016 Sagara et al. Open Access article distributed under the terms of CC BY-NC-ND Terms and Conditions